Astria Therapeutics Inc Ordinary Shares ATXS 深 沪
等待开盘 08-15 09:30:00 美东时间
6.76
-0.110
-1.60%
华盛通- 最 高6.98
- 今 开6.77
- 成交量 41.41万股
- 最 低 6.60
- 昨 收 6.87
- 总市值 3.81亿
- 52周最高 12.92
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.555
- 委 比 81.76%
- 总股本 5643.42万
- 历史最高 1017.60
- 量 比 1.60
- 振 幅 5.53%
- 历史最低 2.36
- 每 手 1
- 风险率 3.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JMP Securities Maintains Market Outperform on Astria Therapeutics, Raises Price Target to $26
JMP Securities analyst Jonathan Wolleben maintains Astria Therapeutics (NASDAQ:ATXS) with a Market Outperform and raises the price target from $25 to $26.
08-13 22:18
Astria Therapeutics Q2 EPS $(0.57) Beats $(0.59) Estimate
Astria Therapeutics (NASDAQ:ATXS) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.59) by 2.9 percent. This is a 32.56 percent decrease over losses of $(0.43) per share from
08-13 04:37
Astria Therapeutics Enters Licensing Deal with Kaken
Astria Therapeutics ( ($ATXS) ) just unveiled an update. On August 6, 2025, Ast...
08-06 20:28
Astria Therapeutics Licenses D&C Rights In Japan To Kaken Pharma For Navenibart In Phase 3 Development For Preventative Treatment Of HAE; Astria To Receive $16M Upfront, With Potential For $16M In Commercialization Milestones
-- Up to $32 Million in Upfront and Milestone Payments, Plus Royalties ---- Kaken Expertise in Commercializing Innovative Therapies Supports Navenibart's Potential to be First-Choice HAE Treatment in Japan ---- Updated
08-06 20:17
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
Allarity Therapeutics received formal acceptance of its patent application for the DRP® companion diagnostic specific to stenoparib from IP Australia. The acceptance covers 40 claims, marking a key step in the company's global strategy to protect the commercialization of its proprietary DRP® platform alongside clinical development. The granted patent will be advertised on June 26, 2025, followed by a three-month opposition period. CEO Thomas Jens...
06-30 12:00
美股大行评级 | 潜在涨幅290.69%！乌龙制药获丰业银行升目标价至47美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140565699993591809.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持乌龙制药(URGN)"跑赢大市"评级，目标价从23美元升至47美元</p> <p>• Guggenheim：维持ADC Therapeutics(ADCT)"买入"评级，目标价从7美元升至10美元</p>
06-16 08:40
Astria Therapeutics Reports Initial Results From Target Enrollment Group In Ongoing ALPHA-SOLAR Long-Term Open-Label Trial Evaluating Navenibart In HAE Patients
-- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction ---- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction –-- Well-Tolerated with a Favorable Safety Profile ---- All Patients Remain on Navenibart
06-13 19:02
Astria Therapeutics To Present Safety And Efficacy Data From Phase 1a And Phase 1b/2 Trials Of Navenibart At C1 Inhibitor Deficiency And Angioedema Workshop
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14th C1 Inhibitor
05-23 20:17
Cantor Fitzgerald Reiterates Overweight on Astria Therapeutics, Maintains $47 Price Target
Cantor Fitzgerald analyst Timur Ivannikov reiterates Astria Therapeutics (NASDAQ:ATXS) with a Overweight and maintains $47 price target.
05-14 22:22
